secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardio Diagnostics Holdings, Inc. (CDIO)
CIK:        0001870144
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001079973-26-000239
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardio Diagnostics holds investor call; highlights $854 CMS rate, new CLIA lab, and India expansion
--------------------------------------------------------------------------------

- Investor presentation reveals $854 final CMS gapfill rate for both Epi+Gen CHD and PrecisionCHD tests.
- New internal CLIA lab reduces initial COGS by ~30%; further reductions expected at scale.
- TAM estimated at ~$176B across both tests, with 146M and 60M eligible Americans respectively.
- Announced partnership with Aimil Ltd and Dr. Lal PathLabs for India expansion of PrecisionCHD.
- Preliminary data on PrecisionCHD presented at AHA and ACC conferences showing INOCA detection and ACS mortality prediction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870144/000107997326000239/0001079973-26-000239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870144/000107997326000239/cdio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-26-000239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer